Researchers at the Hebrew University of Jerusalem and the IDF Medical Corps have discovered a promising new therapeutic ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...

Pierre Laurin Named Executive Chairman of the Board Leadership Team Strengthened as Company Advances Toward Clinical Stage ...

A drug that is currently used for cancer could be the key in treating a disease that has no cure, and a life expectancy of ...

Idiopathic pulmonary fibrosis was associated with 67,843 deaths in ever-employed persons in the US between 2020 and 2022.

The comprehensive study, which tracked data spanning 20 years, revealed that not only does pregnancy not negatively impact ...

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference  Late-breaking oral presentation to highlight further ...

Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF, in which a positive trend was observed in seven out of eight biomarkers ...

Barrow in Furness will soon say goodbye to one of its best 'top welders', Geoff Mattimore, who died of a rare lung condition Idiopathic ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...